Tyro Capital Management LLC boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 0.6% during the third quarter, HoldingsChannel.com reports. The firm owned 1,754,976 shares of the company’s stock after acquiring an additional 10,649 shares during the period. Roivant Sciences makes up about 6.4% of Tyro Capital Management LLC’s portfolio, making the stock its 6th largest holding. Tyro Capital Management LLC’s holdings in Roivant Sciences were worth $20,252,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in ROIV. nVerses Capital LLC acquired a new position in shares of Roivant Sciences in the second quarter worth $34,000. Gladius Capital Management LP purchased a new stake in shares of Roivant Sciences during the 3rd quarter worth about $35,000. Point72 Hong Kong Ltd acquired a new stake in shares of Roivant Sciences during the 2nd quarter valued at about $36,000. US Bancorp DE grew its stake in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares in the last quarter. Finally, Quarry LP acquired a new position in Roivant Sciences in the second quarter worth approximately $53,000. Institutional investors and hedge funds own 64.76% of the company’s stock.
Insider Buying and Selling
In related news, COO Eric Venker sold 100,000 shares of the stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the sale, the chief operating officer now owns 617,470 shares in the company, valued at approximately $7,193,525.50. This trade represents a 13.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $11.82, for a total value of $10,354,320.00. Following the sale, the director now directly owns 22,179,358 shares in the company, valued at approximately $262,160,011.56. This trade represents a 3.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,677,309 shares of company stock valued at $43,283,184. Insiders own 7.90% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Report on Roivant Sciences
Roivant Sciences Price Performance
Roivant Sciences stock opened at $11.90 on Friday. The firm has a market cap of $8.66 billion, a price-to-earnings ratio of 2.10 and a beta of 1.25. The firm has a fifty day moving average price of $11.87 and a two-hundred day moving average price of $11.43. Roivant Sciences Ltd. has a fifty-two week low of $9.69 and a fifty-two week high of $13.06.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
- Five stocks we like better than Roivant Sciences
- Most Volatile Stocks, What Investors Need to Know
- 3 Consumer Discretionary Stocks Ready for a Comeback in 2025
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Top 3 Robotics and Automation Stocks for the Next AI Boom
- What is Forex and How Does it Work?
- Why a Stock Split Could Be a Game-Changer for Casey’s in 2025
Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report).
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.